Skip to main content

Catalyst Calendar

Tue, Aug 11, 2026

1 updates

8:00 AM

Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

tevapharm.com

Wed, Jul 29, 2026

1 updates

7:00 AM

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

tevapharm.com

Thu, Jul 9, 2026

1 updates

8:30 AM

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

tevapharm.com

Tue, Jul 7, 2026

1 updates

7:00 AM

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

tevapharm.com

Thu, Jun 18, 2026

4 updates

5:00 PM

Teva Releases Q2 2026 Aide Memoire

tevapharm.com

4:56 PM

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

tevapharm.com

4:56 PM

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

tevapharm.com

4:30 PM

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

tevapharm.com

Wed, Jun 10, 2026

1 updates

12:03 PM

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

tevapharm.com

Mon, Jun 8, 2026

1 updates

8:00 AM

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

tevapharm.com

Fri, Jun 5, 2026

1 updates

11:30 AM

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

tevapharm.com

Thu, Jun 4, 2026

1 updates

8:30 AM

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

tevapharm.com

Mon, Jun 1, 2026

1 updates

4:30 PM

Teva to Present at the Goldman Sachs Global Healthcare Conference

tevapharm.com